phenoxymethylpenicillin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, 6-aminopenicillanic acid derivatives 2083 87-08-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • penicillin v
  • penicillin v potassium
  • phenopenicillin
  • meropenin
  • phenoxymethylpenicillin
  • phenoxymethylpenicillinic acid
A broad-spectrum penicillin antibiotic used orally in the treatment of mild to moderate infections by susceptible gram-positive organisms.
  • Molecular weight: 350.39
  • Formula: C16H18N2O5S
  • CLOGP: 1.94
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 95.94
  • ALOGS: -2.89
  • ROTB: 5
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 4 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.45 mg/mL Bocci G, Oprea TI, Benet LZ
MRTD (Maximum Recommended Therapeutic Daily Dose) 71.35 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 0.41 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 6.80 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.45 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.84 hours Lombardo F, Berellini G, Obach RS
BA (Bioavailability) 50 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -1.123 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 2.104 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.925 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 2.864 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 50 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 37.280 % High 1
herg hERG pIC50 4.416 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.730 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.133 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 42.290 % High 1
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,GRK3,GSK3B,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK7,MAPK9,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CG,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 44
kinase-selectivity-class AXL,EIF2AK3,GRK2,MAP2K6 4
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 0.531 Moderate 0.73
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.910 High 1
mh-clint Mouse hepatocyte intrinsic clearance 8.414 High 1
mppb Mouse plasma protein binding (% unbound) 37.760 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 2.489 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 32.670 % High 1
rat-kpuu-brain Rat brain Kpuu 0.010 % Moderate 0.73
rh-clint Rat hepatocyte intrinsic clearance 3.802 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 82.290 % High 1
rppb Rat plasma protein binding (% unbound) 30.050 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 939.723 uM High 1

Approvals:

DateAgencyCompanyOrphan
Jan. 13, 1958 FDA WYETH AYERST

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 309.41 17.40 294 8399 463315 90156439
Lip swelling 122.29 17.40 64 8629 38546 90581208
Myocardial depression 119.60 17.40 24 8669 609 90619145
Rash 115.10 17.40 242 8451 795858 89823896
Decorticate posture 114.57 17.40 21 8672 324 90619430
Swelling face 74.47 17.40 62 8631 81290 90538464
Lipase increased 64.63 17.40 28 8665 11083 90608671
Ventricular hypokinesia 57.52 17.40 21 8672 5320 90614434
Gastric cancer 50.91 17.40 19 8674 5117 90614637
Toxic epidermal necrolysis 50.38 17.40 34 8659 32494 90587260
Oral discomfort 50.02 17.40 23 8670 10460 90609294
Hypothermia 46.96 17.40 25 8668 15550 90604204
Eosinophilia 44.61 17.40 30 8663 28503 90591251
Adenovirus reactivation 44.27 17.40 9 8684 244 90619510
Lichen nitidus 44.24 17.40 8 8685 114 90619640
Rash macular 43.00 17.40 30 8663 30250 90589504
Coma scale abnormal 42.21 17.40 17 8676 5609 90614145
Bronchiolitis 38.92 17.40 14 8679 3398 90616356
Drug reaction with eosinophilia and systemic symptoms 37.89 17.40 32 8661 42726 90577028
Cerebral toxoplasmosis 37.57 17.40 11 8682 1394 90618360
Urticaria 36.90 17.40 88 8605 312646 90307108
Intentional overdose 36.50 17.40 45 8648 93789 90525965
Respiratory depression 36.02 17.40 21 8672 15554 90604200
Swollen tongue 35.89 17.40 32 8661 45924 90573830
BK polyomavirus test positive 35.71 17.40 7 8686 157 90619597
Jugular vein occlusion 34.87 17.40 6 8687 63 90619691
Actinomycotic sepsis 32.49 17.40 7 8686 253 90619501
Epstein-Barr virus infection reactivation 31.70 17.40 10 8683 1627 90618127
Hepatocellular injury 30.56 17.40 24 8669 28934 90590820
Hypersensitivity 30.21 17.40 104 8589 454573 90165181
Unresponsive to stimuli 28.69 17.40 26 8667 38095 90581659
Graft versus host disease in gastrointestinal tract 28.63 17.40 12 8681 4376 90615378
Acute respiratory distress syndrome 28.61 17.40 23 8670 28663 90591091
Eye swelling 28.12 17.40 23 8670 29363 90590391
Breakthrough haemolysis 27.38 17.40 6 8687 235 90619519
Herpes zoster infection neurological 27.31 17.40 7 8686 540 90619214
Gingival abscess 27.08 17.40 8 8685 1045 90618709
Pancreatitis 26.36 17.40 33 8660 69793 90549961
Encephalopathy 26.13 17.40 27 8666 46417 90573337
Thrombotic microangiopathy 25.68 17.40 17 8676 15726 90604028
Plagiocephaly 24.95 17.40 5 8688 126 90619628
Focal nodular hyperplasia 24.92 17.40 7 8686 765 90618989
Cytomegalovirus infection reactivation 24.87 17.40 13 8680 7787 90611967
Hepatobiliary infection 24.82 17.40 4 8689 27 90619727
Agranulocytosis 24.64 17.40 23 8670 34979 90584775
Pneumonia parainfluenzae viral 24.60 17.40 6 8687 378 90619376
Rheumatoid arthritis 24.49 17.40 3 8690 362611 90257143
Joint swelling 24.25 17.40 9 8684 503291 90116463
Herpes simplex test positive 24.21 17.40 6 8687 404 90619350
Minimal residual disease 23.87 17.40 6 8687 428 90619326
Haemolysis 23.81 17.40 13 8680 8497 90611257
Lichenoid keratosis 23.75 17.40 9 8684 2525 90617229
Cellulitis staphylococcal 23.54 17.40 7 8686 936 90618818
Graft versus host disease in skin 23.36 17.40 10 8683 3843 90615911
Drug ineffective 23.09 17.40 63 8630 1384235 89235519
Pulmonary function test abnormal 23.07 17.40 9 8684 2730 90617024
Herpes simplex reactivation 23 17.40 7 8686 1012 90618742
Lichenification 22.80 17.40 6 8687 513 90619241
Cross sensitivity reaction 22.70 17.40 9 8684 2848 90616906
Mouth swelling 22.64 17.40 11 8682 5651 90614103
Granulomatous dermatitis 22.41 17.40 5 8688 213 90619541
Hepatic enzyme increased 22.03 17.40 4 8689 360732 90259022
Subacute combined cord degeneration 21.91 17.40 5 8688 236 90619518
Infusion related reaction 20.84 17.40 7 8686 416773 90202981
Vipoma 20.52 17.40 4 8689 87 90619667
Oligohydramnios 20.14 17.40 11 8682 7190 90612564
Injection site hypersensitivity 19.74 17.40 8 8685 2679 90617075
Acute kidney injury 19.28 17.40 71 8622 320316 90299438
Growth retardation 19.16 17.40 7 8686 1776 90617978
Dermatitis bullous 18.94 17.40 12 8681 10304 90609450
Intravascular haemolysis 18.92 17.40 5 8688 435 90619319
Infection reactivation 18.58 17.40 7 8686 1933 90617821
Suicide attempt 18.53 17.40 29 8664 75370 90544384
Jaundice 18.47 17.40 19 8674 32498 90587256
Acute graft versus host disease in skin 18.30 17.40 9 8684 4747 90615007
Vitiligo 18.01 17.40 7 8686 2103 90617651
Conversion disorder 17.89 17.40 7 8686 2139 90617615

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neuritis 204.23 17.93 72 10841 6148 42604274
Pulmonary vasculitis 203.72 17.93 72 10841 6194 42604228
Neurological symptom 174.42 17.93 73 10840 9918 42600504
Respiratory symptom 166.98 17.93 73 10840 11033 42599389
Eosinophilic granulomatosis with polyangiitis 163.94 17.93 67 10846 8571 42601851
Total lung capacity abnormal 163.48 17.93 56 10857 4387 42606035
Pulmonary alveolar haemorrhage 146.89 17.93 73 10840 14743 42595679
Forced expiratory volume decreased 144.17 17.93 59 10854 7571 42602851
Antineutrophil cytoplasmic antibody positive 133.70 17.93 48 10865 4317 42606105
Pulmonary fibrosis 131.37 17.93 83 10830 26598 42583824
Obstructive airways disorder 129.41 17.93 80 10833 24679 42585743
Vasculitis 121.13 17.93 69 10844 18325 42592097
Mycotic allergy 110.39 17.93 43 10870 4848 42605574
Mite allergy 109.09 17.93 43 10870 5003 42605419
Sleep disorder due to a general medical condition 108.33 17.93 63 10850 17390 42593032
Dust allergy 106.79 17.93 43 10870 5289 42605133
Hypothyroidism 106.00 17.93 78 10835 32006 42578416
Conjunctivitis allergic 105.87 17.93 44 10869 5867 42604555
Spirometry abnormal 104.79 17.93 42 10871 5104 42605318
Haemoptysis 102.77 17.93 89 10824 46078 42564344
Spinal muscular atrophy 100.76 17.93 23 10890 393 42610029
Full blood count abnormal 99.52 17.93 73 10840 29803 42580619
Lung disorder 90.09 17.93 84 10829 47839 42562583
Acute generalised exanthematous pustulosis 90.08 17.93 44 10869 8551 42601871
Normochromic normocytic anaemia 88.01 17.93 44 10869 8987 42601435
Wheezing 82.40 17.93 85 10828 54696 42555726
Nodule 77.12 17.93 45 10868 12489 42597933
Pneumococcal sepsis 76.37 17.93 24 10889 1431 42608991
Drug hypersensitivity 73.88 17.93 108 10805 99281 42511141
Asthma 71.70 17.93 84 10829 62230 42548192
Disease complication 69.31 17.93 27 10886 3043 42607379
Motor neurone disease 69.18 17.93 18 10895 541 42609881
Increased bronchial secretion 65.13 17.93 24 10889 2322 42608100
Stoma closure 63.81 17.93 15 10898 293 42610129
Respiratory tract infection bacterial 62.26 17.93 22 10891 1887 42608535
Sputum increased 61.58 17.93 25 10888 3138 42607284
Arteriosclerosis coronary artery 60.74 17.93 45 10868 18632 42591790
Lower respiratory tract infection bacterial 59.48 17.93 16 10897 548 42609874
Nocardiosis 58.70 17.93 28 10885 5162 42605260
Loss of personal independence in daily activities 58.70 17.93 68 10845 49748 42560674
Metabolic disorder 57.74 17.93 27 10886 4761 42605661
Arteriosclerosis 57.73 17.93 43 10870 17946 42592476
Ischaemic cerebral infarction 57.67 17.93 20 10893 1623 42608799
Bronchial disorder 56.84 17.93 19 10894 1379 42609043
Chest X-ray abnormal 56.16 17.93 26 10887 4482 42605940
Capillaritis 55.31 17.93 21 10892 2207 42608215
Therapeutic product effect incomplete 52.54 17.93 77 10836 70862 42539560
Lymphadenectomy 51.81 17.93 14 10899 488 42609934
Brief psychotic disorder with marked stressors 49.78 17.93 12 10901 262 42610160
Resuscitation 48.20 17.93 18 10895 1807 42608615
Scoliosis 41.99 17.93 19 10894 3107 42607315
Lung consolidation 41.14 17.93 24 10889 6653 42603769
Cerebral ischaemia 40.21 17.93 24 10889 6935 42603487
Condition aggravated 40.15 17.93 152 10761 260602 42349820
Drug ineffective 39.56 17.93 63 10850 630134 41980288
Anxiety 39.43 17.93 91 10822 118469 42491953
Drug reaction with eosinophilia and systemic symptoms 39.14 17.93 51 10862 42024 42568398
Brain injury 38.11 17.93 24 10889 7631 42602791
Hypovitaminosis 37.27 17.93 12 10901 774 42609648
Demyelination 36.77 17.93 18 10895 3511 42606911
Productive cough 36.76 17.93 55 10858 51512 42558910
Motor dysfunction 36.74 17.93 24 10889 8122 42602300
Staphylococcal mediastinitis 35.99 17.93 7 10906 52 42610370
Morganella infection 35.80 17.93 11 10902 608 42609814
Pleocytosis 35.03 17.93 11 10902 654 42609768
Bronchial haemorrhage 34.41 17.93 11 10902 693 42609729
Swelling face 31.41 17.93 37 10876 27517 42582905
Intestinal ischaemia 31.37 17.93 23 10890 9365 42601057
Rash 31.34 17.93 147 10766 276807 42333615
Prothrombin level abnormal 27.20 17.93 6 10907 87 42610335
Graft versus host disease 26.88 17.93 24 10889 12901 42597521
Muscle atrophy 26.85 17.93 20 10893 8341 42602081
Thrombotic microangiopathy 26.00 17.93 25 10888 14757 42595665
Atelectasis 25.46 17.93 28 10885 19333 42591089
Inflammation 25.41 17.93 37 10876 33810 42576612
Thrombosis 24.32 17.93 54 10859 68457 42541965
Pain in extremity 23.28 17.93 88 10825 150516 42459906
Hypoxia 22.55 17.93 53 10860 69733 42540689
Toxoplasmosis 22.32 17.93 10 10903 1597 42608825
Pulmonary embolism 22.00 17.93 74 10839 119538 42490884
Toxicity to various agents 21.96 17.93 16 10897 229120 42381302
Dyspnoea 21.78 17.93 190 10723 442431 42167991
Fall 21.68 17.93 17 10896 234503 42375919
Meningoencephalitis amoebic 21.68 17.93 6 10907 229 42610193
Meningitis meningococcal 21.55 17.93 5 10908 92 42610330
Axonal neuropathy 21.46 17.93 9 10904 1226 42609196
Skin exfoliation 21.05 17.93 38 10875 41515 42568907
Plasma cell myeloma 20.98 17.93 41 10872 47537 42562885
Acanthamoeba infection 20.83 17.93 7 10906 516 42609906
Sleep disorder 20.67 17.93 41 10872 48054 42562368
Sinusitis bacterial 20.27 17.93 7 10906 561 42609861
Splenic embolism 20.25 17.93 6 10907 293 42610129
Cytomegalovirus oesophagitis 20.06 17.93 7 10906 578 42609844
Eosinophil count decreased 19.80 17.93 12 10901 3564 42606858
Lung infiltration 19.74 17.93 21 10892 13968 42596454
Secretion discharge 19.60 17.93 16 10897 7619 42602803
Vasogenic cerebral oedema 19.52 17.93 8 10905 1028 42609394
Acute lymphocytic leukaemia recurrent 19.45 17.93 12 10901 3679 42606743
Osteomyelitis chronic 19.20 17.93 6 10907 351 42610071
Injury 19.13 17.93 26 10887 22290 42588132
Mechanical ventilation 19.01 17.93 10 10903 2267 42608155
Mouth ulceration 18.57 17.93 21 10892 14942 42595480
Hypocalvaria 18.54 17.93 4 10909 52 42610370
Antipsychotic drug level decreased 18.43 17.93 8 10905 1185 42609237
Conjunctivitis bacterial 18.43 17.93 5 10908 177 42610245
Disseminated varicella zoster virus infection 18.09 17.93 7 10906 774 42609648
Circulatory collapse 17.97 17.93 26 10887 23610 42586812

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pulmonary vasculitis 236.55 15.26 73 17948 6487 110564791
Neuritis 227.90 15.26 73 17948 7326 110563952
Neurological symptom 195.15 15.26 79 17942 15529 110555749
Total lung capacity abnormal 190.93 15.26 57 17964 4526 110566752
Eosinophilic granulomatosis with polyangiitis 183.07 15.26 68 17953 10618 110560660
Respiratory symptom 181.21 15.26 74 17947 14871 110556407
Pulmonary alveolar haemorrhage 159.94 15.26 74 17947 20076 110551202
Obstructive airways disorder 156.23 15.26 96 17925 46053 110525225
Antineutrophil cytoplasmic antibody positive 151.89 15.26 49 17972 5027 110566251
Forced expiratory volume decreased 142.05 15.26 60 17961 13116 110558162
Mite allergy 125.96 15.26 44 17977 5759 110565519
Mycotic allergy 124.86 15.26 44 17977 5910 110565368
Dust allergy 124.52 15.26 44 17977 5957 110565321
Spirometry abnormal 124.41 15.26 43 17978 5454 110565824
Conjunctivitis allergic 122.01 15.26 45 17976 6886 110564392
Lip swelling 116.96 15.26 83 17938 50584 110520694
Vasculitis 114.76 15.26 72 17949 35801 110535477
Hypothyroidism 110.44 15.26 93 17928 72806 110498472
Haemoptysis 110.10 15.26 92 17929 71262 110500016
Normochromic normocytic anaemia 106.89 15.26 49 17972 13008 110558270
Spinal muscular atrophy 104.72 15.26 22 17999 405 110570873
Myocardial depression 103.44 15.26 24 17997 708 110570570
Decorticate posture 102.33 15.26 21 18000 343 110570935
Full blood count abnormal 98.55 15.26 78 17943 55974 110515304
Rash 98.29 15.26 325 17696 820639 109750639
Swelling face 95.30 15.26 95 17926 92226 110479052
Drug hypersensitivity 86.74 15.26 213 17808 453877 110117401
Sleep disorder due to a general medical condition 82.06 15.26 68 17953 52044 110519234
Pneumococcal sepsis 81.36 15.26 25 17996 2187 110569091
Pulmonary fibrosis 73.73 15.26 87 17934 101955 110469323
Acute generalised exanthematous pustulosis 73.12 15.26 45 17976 21619 110549659
Drug reaction with eosinophilia and systemic symptoms 73.02 15.26 78 17943 82017 110489261
Motor neurone disease 72.62 15.26 18 18003 706 110570572
Arteriosclerosis coronary artery 69.43 15.26 46 17975 25072 110546206
Stoma closure 65.89 15.26 15 18006 406 110570872
Arteriosclerosis 65.20 15.26 44 17977 24723 110546555
Lung disorder 63.57 15.26 109 17912 179938 110391340
Respiratory tract infection bacterial 62.92 15.26 21 18000 2395 110568883
Capillaritis 62.72 15.26 21 18000 2418 110568860
Drug ineffective 62.36 15.26 95 17926 1520445 109050833
Nocardiosis 60.98 15.26 28 17993 7458 110563820
Increased bronchial secretion 59.92 15.26 23 17998 3925 110567353
Nodule 58.62 15.26 46 17975 32585 110538693
Lower respiratory tract infection bacterial 56.27 15.26 16 18005 1069 110570209
Bronchial disorder 56.24 15.26 20 18001 2756 110568522
Ischaemic cerebral infarction 55.09 15.26 20 18001 2925 110568353
Sputum increased 54.78 15.26 24 17997 5727 110565551
Disease complication 54.48 15.26 24 17997 5803 110565475
Thrombotic microangiopathy 52.16 15.26 41 17980 29108 110542170
Brief psychotic disorder with marked stressors 51.91 15.26 12 18009 348 110570930
Chest X-ray abnormal 51.68 15.26 26 17995 8461 110562817
Wheezing 48.92 15.26 120 17901 255110 110316168
Resuscitation 47.80 15.26 18 18003 2915 110568363
Metabolic disorder 46.45 15.26 26 17995 10484 110560794
Brain injury 45.49 15.26 28 17993 13448 110557830
Lymphadenectomy 42.59 15.26 14 18007 1522 110569756
Eosinophilia 41.18 15.26 49 17972 57887 110513391
Morganella infection 39.98 15.26 13 18008 1366 110569912
Hypovitaminosis 39.25 15.26 13 18008 1447 110569831
Staphylococcal mediastinitis 39.03 15.26 7 18014 53 110571225
Lung consolidation 38.54 15.26 23 17998 10453 110560825
Rash macular 38.41 15.26 39 17982 38647 110532631
Lichen nitidus 38.25 15.26 8 18013 144 110571134
Cerebral ischaemia 37.96 15.26 24 17997 12080 110559198
Granulomatous dermatitis 37.68 15.26 10 18011 516 110570762
Loss of personal independence in daily activities 37.02 15.26 78 17943 149942 110421336
Oral discomfort 34.41 15.26 22 17999 11289 110559989
Scoliosis 34.29 15.26 20 18001 8713 110562565
Joint swelling 33.69 15.26 15 18006 442830 110128448
Productive cough 32.45 15.26 63 17958 114242 110457036
Eye swelling 32.23 15.26 33 17988 33015 110538263
Ventricular hypokinesia 32.11 15.26 21 18000 11193 110560085
Fall 31.68 15.26 31 17990 603451 109967827
Hepatic enzyme increased 31.27 15.26 7 18014 320885 110250393
Anxiety 31.22 15.26 125 17896 344953 110226325
Brain abscess 30.60 15.26 17 18004 6757 110564521
Infusion related reaction 30.45 15.26 12 18009 381150 110190128
Dyspnoea 30.37 15.26 294 17727 1106578 109464700
Swollen tongue 30.30 15.26 43 17978 60319 110510959
Haemolysis 30.16 15.26 23 17998 15616 110555662
Adenovirus reactivation 29.94 15.26 9 18012 731 110570547
Jugular vein occlusion 29.90 15.26 6 18015 87 110571191
Thrombosis 29.77 15.26 59 17962 108603 110462675
Eosinophil count decreased 29.66 15.26 16 18005 6002 110565276
Toxic skin eruption 29.64 15.26 29 17992 27486 110543792
Pleocytosis 29.63 15.26 11 18010 1713 110569565
Intestinal ischaemia 29.47 15.26 23 17998 16156 110555122
Encephalopathy 28.48 15.26 49 17972 81006 110490272
Graft versus host disease 28.47 15.26 24 17997 18782 110552496
Hepatobiliary infection 28.35 15.26 5 18016 34 110571244
Bronchial haemorrhage 28.13 15.26 10 18011 1377 110569901
Asthma 27.91 15.26 97 17924 250194 110321084
Toxic epidermal necrolysis 27.87 15.26 40 17981 56687 110514591
Demyelination 27.84 15.26 18 18003 9411 110561867
Wound 27.60 15.26 3 18018 234434 110336844
BK polyomavirus test positive 27.53 15.26 7 18014 305 110570973
Coma scale abnormal 27.33 15.26 18 18003 9708 110561570
Contraindicated product administered 27.24 15.26 4 18017 248263 110323015
Muscle atrophy 26.68 15.26 20 18001 13234 110558044
Therapeutic product effect incomplete 26.06 15.26 88 17933 223717 110347561
Rash papular 25.87 15.26 27 17994 27612 110543666
Bronchiolitis 25.40 15.26 14 18007 5479 110565799
Actinomycotic sepsis 25.04 15.26 6 18015 204 110571074
Meningoencephalitis amoebic 24.14 15.26 6 18015 238 110571040
Mobility decreased 23.49 15.26 5 18016 237417 110333861
Hypothermia 23.39 15.26 25 17996 26277 110545001
Plasma cell myeloma 23.37 15.26 39 17982 62897 110508381
Treatment failure 23.37 15.26 8 18013 277226 110294052
Cerebral toxoplasmosis 23.26 15.26 11 18010 3131 110568147
Breakthrough haemolysis 23.17 15.26 6 18015 281 110570997
Motor dysfunction 23.13 15.26 24 17997 24382 110546896
Intravascular haemolysis 23.11 15.26 8 18013 1019 110570259
Rheumatoid arthritis 23.01 15.26 10 18011 299603 110271675
Pharyngeal oedema 22.91 15.26 20 18001 16408 110554870
Acanthamoeba infection 22.74 15.26 7 18014 616 110570662
Gingival abscess 22.66 15.26 8 18013 1079 110570199
Graft versus host disease in skin 22.53 15.26 15 18006 8239 110563039
Cross sensitivity reaction 22.52 15.26 13 18008 5554 110565724
Hepatocellular injury 22.41 15.26 34 17987 50608 110520670
Bone marrow transplant rejection 22.36 15.26 6 18015 323 110570955
Pulmonary embolism 22.09 15.26 81 17940 214393 110356885
Hypoxia 21.78 15.26 58 17963 129457 110441821
Mouth swelling 21.62 15.26 14 18007 7340 110563938
Arthropathy 21.45 15.26 10 18011 287512 110283766
Tonsil cancer 21.23 15.26 8 18013 1298 110569980
Rash maculo-papular 21.17 15.26 41 17980 74181 110497097
Skin exfoliation 20.95 15.26 45 17976 87606 110483672
Gastric cancer 20.81 15.26 16 18005 10992 110560286
Antipsychotic drug level decreased 20.62 15.26 8 18013 1404 110569874
Alopecia 19.98 15.26 18 18003 364735 110206543
Agranulocytosis 19.97 15.26 36 17985 61724 110509554
Toxoplasmosis 19.95 15.26 10 18011 3229 110568049
Axonal neuropathy 19.92 15.26 9 18012 2309 110568969
Meningitis meningococcal 19.77 15.26 5 18016 213 110571065
Mechanical ventilation 19.75 15.26 10 18011 3297 110567981
Atelectasis 19.68 15.26 27 17994 36685 110534593
Herpes zoster infection neurological 19.60 15.26 6 18015 518 110570760
Cytomegalovirus oesophagitis 19.58 15.26 7 18014 979 110570299
Acute lymphocytic leukaemia recurrent 19.47 15.26 12 18009 5775 110565503
Duodenal ulcer perforation 19.17 15.26 3 18018 177697 110393581
Drug abuse 19.13 15.26 3 18018 177408 110393870
Graft versus host disease in gastrointestinal tract 19.10 15.26 14 18007 8954 110562324
Therapeutic product effect decreased 19.00 15.26 8 18013 244308 110326970
Haemolytic uraemic syndrome 18.48 15.26 11 18010 4974 110566304
Herpes simplex test positive 18.42 15.26 6 18015 634 110570644
Weight increased 18.28 15.26 25 17996 419619 110151659
Pneumonia parainfluenzae viral 18.05 15.26 6 18015 675 110570603
Parvovirus B19 infection 18.05 15.26 9 18012 2872 110568406
Intentional product use issue 17.91 15.26 9 18012 247897 110323381
Pyrexia 17.85 15.26 224 17797 898041 109673237
Disseminated varicella zoster virus infection 17.80 15.26 7 18014 1274 110570004
Impaired healing 17.79 15.26 5 18016 196712 110374566
Lung infiltration 17.78 15.26 21 18000 24607 110546671
Arthritis 17.70 15.26 3 18018 167583 110403695
Vipoma 17.61 15.26 4 18017 107 110571171
Prostatism 17.21 15.26 4 18017 119 110571159
Subacute combined cord degeneration 17.18 15.26 5 18016 363 110570915
Osteomyelitis chronic 17.13 15.26 6 18015 791 110570487
Vasogenic cerebral oedema 17.00 15.26 8 18013 2250 110569028
Herpes simplex reactivation 16.88 15.26 7 18014 1461 110569817
Unresponsive to stimuli 16.70 15.26 34 17987 63756 110507522
Nasopharyngitis 16.67 15.26 24 17997 394337 110176941
Conversion disorder 16.64 15.26 8 18013 2362 110568916
Cholestasis 16.44 15.26 34 17987 64484 110506794
Endotracheal intubation 16.37 15.26 11 18010 6133 110565145
Product use issue 16.34 15.26 16 18005 311679 110259599
Focal nodular hyperplasia 16.33 15.26 6 18015 907 110570371
Injection site hypersensitivity 16.32 15.26 8 18013 2463 110568815
Vaccination failure 16.21 15.26 8 18013 2498 110568780
Growth retardation 15.98 15.26 8 18013 2574 110568704
Pain 15.91 15.26 91 17930 954864 109616414
Abdominal discomfort 15.65 15.26 25 17996 393833 110177445
Meningococcal sepsis 15.54 15.26 4 18017 183 110571095
Pharyngeal swelling 15.49 15.26 14 18007 12018 110559260
Condition aggravated 15.34 15.26 185 17836 734651 109836627

FDA Adverse Event Reporting System (Pediatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Plagiocephaly 35.41 17.99 6 6 72 113869

Pharmacologic Action:

SourceCodeDescription
ATC J01CE02 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
BETA-LACTAM ANTIBACTERIALS, PENICILLINS
Beta-lactamase sensitive penicillins
FDA CS M0016152 Penicillins
FDA EPC N0000175497 Penicillin-class Antibacterial
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents
CHEBI has role CHEBI:33281 antimicrobial agent
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:35441 antiinfective agent
CHEBI has role CHEBI:35554 cardiovascular drug

Related Drugs by ATC class:

J01CE Beta-lactamase sensitive penicillins 9 drugs
azidocillinbenzathine benzylpenicillinbenzathine phenoxymethylpenicillinbenzylpenicillinclometocillinpenamecillinpheneticillinprocaine benzylpenicillinpropicillin

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Acute otitis media indication 3110003
Infection of skin AND/OR subcutaneous tissue indication 19824006
Gingivostomatitis indication 20607006
Scarlet fever indication 30242009 DOID:8596
Streptococcal tonsillitis indication 41582007
Erysipelas indication 44653001 DOID:11330
Upper respiratory infection indication 54150009
Streptococcus pyogenes infection indication 302809008
Infective otitis media indication 312218008
Fusospirochetal pharyngitis indication 399095008
Pharyngitis indication 405737000 DOID:2275
Infection due to Staphylococcus aureus indication 406602003
Pneumococcal Acute Otitis Media indication
Upper Respiratory Pneumococcal Infection indication
Infection Prevention from Tooth Extraction indication
Rheumatic Fever Prevention indication
Upper Respiratory Streptococcal Infection indication
Actinomycotic infection off-label use 11817007 DOID:8478
Lyme disease off-label use 23502006 DOID:11729
Infection due to anaerobic bacteria off-label use 423451008
Pneumococcal Infection Prevention in Sickle Cell Disease off-label use
Kidney disease contraindication 90708001 DOID:557
Infectious mononucleosis contraindication 271558008 DOID:8568
Pseudomembranous enterocolitis contraindication 397683000




🐶 Veterinary Drug Use

SpeciesUseRelation
Cats Respiratory infections caused by pathogens Indication
Cats Urogenital infections caused by pathogens Indication
Cats Skin and soft tissue infections caused by pathogens Indication
Cats Septicemia caused by pathogens Indication
Dogs Treatment of respiratory, urogenital, skin, and soft tissue infections and septicemia caused by pathogens Indication

🐶 Veterinary products

ProductApplicantIngredients
Penicillin VK Filmtab 250 mg Boehringer lngelheim Animal Health USA Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.79 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Bacterial penicillin-binding protein Enzyme INHIBITOR CHEMBL CHEMBL
Penicillin-binding protein 1A Enzyme WOMBAT-PK

External reference:

IDSource
N0000011298 NUI
D05411 KEGG_DRUG
132-98-9 SECONDARY_CAS_RN
4017436 VANDF
C0030840 UMLSCUI
CHEBI:27446 CHEBI
PNV PDB_CHEM_ID
CHEMBL615 ChEMBL_ID
CHEMBL1200852 ChEMBL_ID
DB00417 DRUGBANK_ID
10920 IUPHAR_LIGAND_ID
6869 PUBCHEM_CID
203195 RXNORM
179406 MMSL
2179 MMSL
5248 MMSL
d07730 MMSL
002684 NDDF
002686 NDDF
372725003 SNOMEDCT_US
39359008 SNOMEDCT_US
56723006 SNOMEDCT_US
D010404 MESH_DESCRIPTOR_UI
518 INN_ID
Z61I075U2W UNII
Z61I075U2W INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Penicillin V Potassium HUMAN PRESCRIPTION DRUG LABEL 1 0093-1172 TABLET 250 mg ORAL ANDA 15 sections
Penicillin V Potassium HUMAN PRESCRIPTION DRUG LABEL 1 0093-1174 TABLET 500 mg ORAL ANDA 15 sections
Penicillin V Potassium HUMAN PRESCRIPTION DRUG LABEL 1 0093-4125 POWDER, FOR SOLUTION 125 mg ORAL ANDA 15 sections
Penicillin V Potassium HUMAN PRESCRIPTION DRUG LABEL 1 0093-4127 POWDER, FOR SOLUTION 250 mg ORAL ANDA 15 sections
Penicillin V Potassium HUMAN PRESCRIPTION DRUG LABEL 1 0143-9836 TABLET, FILM COATED 500 mg ORAL ANDA 15 sections
Penicillin V Potassium HUMAN PRESCRIPTION DRUG LABEL 1 0143-9837 TABLET, FILM COATED 250 mg ORAL ANDA 15 sections
Penicillin V Potassium HUMAN PRESCRIPTION DRUG LABEL 1 0440-2055 TABLET 250 mg ORAL ANDA 14 sections
Penicillin V Potassium HUMAN PRESCRIPTION DRUG LABEL 1 0440-8055 TABLET 250 mg ORAL ANDA 14 sections
Penicillin V Potassium HUMAN PRESCRIPTION DRUG LABEL 1 0440-8056 TABLET 500 mg ORAL ANDA 14 sections
Penicillin V Potassium HUMAN PRESCRIPTION DRUG LABEL 1 10544-075 TABLET, FILM COATED 500 mg ORAL ANDA 14 sections
Penicillin V Potassium HUMAN PRESCRIPTION DRUG LABEL 1 10544-296 TABLET 250 mg ORAL ANDA 15 sections
Penicillin V Potassium HUMAN PRESCRIPTION DRUG LABEL 1 10544-297 TABLET 500 mg ORAL ANDA 15 sections
Penicillin V Potassium HUMAN PRESCRIPTION DRUG LABEL 1 10544-500 TABLET 500 mg ORAL ANDA 15 sections
Penicillin V Potasium HUMAN PRESCRIPTION DRUG LABEL 1 10544-975 TABLET 500 mg ORAL ANDA 16 sections
Penicillin V Potassium Human Prescription Drug Label 1 16714-234 TABLET, FILM COATED 250 mg ORAL ANDA 14 sections
Penicillin V Potassium Human Prescription Drug Label 1 16714-235 TABLET, FILM COATED 500 mg ORAL ANDA 14 sections
Penicillin V Potassium HUMAN PRESCRIPTION DRUG LABEL 1 21695-318 TABLET 500 mg ORAL ANDA 14 sections
Penicillin V Potassium HUMAN PRESCRIPTION DRUG LABEL 1 21695-559 POWDER, FOR SOLUTION 250 mg ORAL ANDA 14 sections
Penicillin V Potassium HUMAN PRESCRIPTION DRUG LABEL 1 21695-772 POWDER, FOR SOLUTION 125 mg ORAL ANDA 14 sections
Penicillin V Potassium HUMAN PRESCRIPTION DRUG LABEL 1 33261-134 TABLET 250 mg ORAL ANDA 14 sections
Penicillin V Potassium HUMAN PRESCRIPTION DRUG LABEL 1 33261-138 TABLET 500 mg ORAL ANDA 14 sections
Penicillin V Potassium HUMAN PRESCRIPTION DRUG LABEL 1 42708-098 TABLET, FILM COATED 500 mg ORAL ANDA 14 sections
Penicillin V Potassium HUMAN PRESCRIPTION DRUG LABEL 1 43063-557 TABLET, FILM COATED 500 mg ORAL ANDA 14 sections
Penicillin V Potassium HUMAN PRESCRIPTION DRUG LABEL 1 43063-557 TABLET, FILM COATED 500 mg ORAL ANDA 14 sections
Penicillin V Potassium HUMAN PRESCRIPTION DRUG LABEL 1 43063-576 TABLET, FILM COATED 500 mg ORAL ANDA 14 sections
Penicillin V Potassium HUMAN PRESCRIPTION DRUG LABEL 1 43063-576 TABLET, FILM COATED 500 mg ORAL ANDA 14 sections
Penicillin V Potassium HUMAN PRESCRIPTION DRUG LABEL 1 43063-614 TABLET, FILM COATED 500 mg ORAL ANDA 14 sections
Penicillin V Potassium HUMAN PRESCRIPTION DRUG LABEL 1 43063-614 TABLET, FILM COATED 500 mg ORAL ANDA 14 sections
Penicillin V Potassium HUMAN PRESCRIPTION DRUG LABEL 1 43063-622 TABLET, FILM COATED 250 mg ORAL ANDA 14 sections
Penicillin V Potassium HUMAN PRESCRIPTION DRUG LABEL 1 43063-622 TABLET, FILM COATED 250 mg ORAL ANDA 14 sections